AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01714232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freestyle Freedom® BGMS
Description: Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
Study NCT03775759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tricuspid valve repair or replacement
Description: Available rings used at Duke include the Tri-Ad™ Adams Tricuspid Ring by Medtronic, the TAILOR™ FLEXIBLE ANNULOPLASTY RING by St. Jude Medical/Abbott, and the Carpentier-Edwards Physio II Ring by Edwards LifeSciences. Available valves used at Duke include the Mosaic™ Mitral Orbutrator by Medtronic, the Carpentier-Edwardes PERIMOUNT Magna Mitral Ease Pericardial Bioprosthesis by Edwards LifeSciences, the On-X Mitral Valve, by CryoLife, the Carbomedics Prosthetic Heart Valve by LivaNova, and the St. Jude Medical™ Mechanical Heart Valve by St. Jude Medical/Abbott.
Study NCT03775759 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical management of tricuspid regurgitation
Description: The medical therapy involved includes inotropic medications and diuretic medications, which are standard of care for patients in this population.
Study NCT02864810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]GP1
Description: \[18F\]GP1 PET/CT imaging for detecting thromboembolism
Study NCT03673657 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Early Nutrition Intervention from the start of CCRT
Description: Nutrition counseling and oral nutritional supplements from the start of radiotherapy; weekly counseling sessions; daily energy intake of approximately 30 kcal/kg.
Study NCT03673657 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy
Description: Definitive thoracic radiotherapy with total radiation doses of 60-68 Gy
Study NCT03673657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Weekly DP chemotherapy concurrent with thoracic radiotherapy
Description: Weekly docetaxel (25mg/㎡) and nedaplatin (25mg/㎡) concurrent with thoracic radiotherapy
Study NCT00635063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD 923
Study NCT00635063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD 923
Study NCT03913819 — intervention group
Intervention type: DRUG
Intervention: First line treatment: oral NSAID and anticholinergic agents
Description: oral NSAID and anticholinergic agents
Study NCT03913819 — intervention group
Intervention type: DRUG
Intervention: Second line treatment: additional treatment for pain control
Description: Gabapentin, tramadol, Lyrica
Study NCT03913819 — intervention group
Intervention type: DRUG
Intervention: Third line treatment: A course of intravesical hyaluronate will be given.
Description: A course of intravesical hyaluronate will be given.
Study NCT03913819 — intervention group
Intervention type: PROCEDURE
Intervention: Fourth line treatment: surgical intervention
Description: Consideration of hydrodistention and augmentation cystoplasty
Study NCT03090607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aluvra™
Description: Endoscopic injection of bulking agent to the lower esophageal sphincter
Study NCT03090607 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Endoscopic injection of saline
Study NCT01459562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NI-0501
Study NCT01459562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00355810 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo followed by Lactobacillus plantarum MF 1298
Description: placebo during 3 weeks, washout period 4 weeks, Lactobacillus plantarum MF1298 during 3 weeks
Study NCT00355810 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum MF1298 followed by placebo
Description: Lactobacillus plantarum MF1298 during 3 weeks, washout period 4 weeks, placebo during 3 weeks
Study NCT02373033 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Natural food folate
Description: Consumed folate-rich foods (providing additional 250 μg/d folate).
Study NCT02373033 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid
Description: Received a folic acid supplement (providing additional 500 μg/d folic acid).
Study NCT02373033 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Apple juice
Description: Received apple juice containing no folate or folic acid.
Study NCT01064050 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: silicone trachea-bronchial stent Dumon (Novatech)
Description: Bronchial desobstruction under interventional bronchoscopy, for inclusion, with the insertion of silicone stent trachea-bronchial covering the entire tumor area
Study NCT02185716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.25 %
Study NCT02185716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine 0.5%
Study NCT00978263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin-based Oral Antidiabetic Drugs
Study NCT00978263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine
Study NCT02679235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POST Triheptanoin
Description: The target daily dose of triheptanoin will be 1 g/kg/d, or approximately 70 g/d during 28±2 days. It will be divided into four daily doses, one of which will be consumed at each meal and one with an evening snack.
Study NCT04293796 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted biopsy
Description: The vacuum-assisted (7-10G), minimal invasive biopsy (VAB), either guided by ultrasound, after neoadjuvant systemic treatment on patients with clinical complete response on primary breast cancer management we recommend to take at least 12 biopsies with 7-10G needle sizes with sentinel lymph node biopsy.
Study NCT03368456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: S4E
Description: S4E application was developed in collaboration with youth in Southeast Michigan. S4E aims to prevent and reduce HIV/STI risk behaviors, including drug use and sexual risk behaviors, and increase HIV/STI testing among youth. Content produced for the application is based on scientific prevention principles in conjunction with youth input. To date, we have developed modules focused on youth alcohol \& drug use, HIV \& STIs and a forthcoming module on tobacco prevention and cessation.
Study NCT03368456 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Participants in Usual Care (i.e., Control Condition) will not receive the S4E intervention from the study staff. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources, and reproductive and healthcare services.
Study NCT00935688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid diagnostic test
Description: Dual species test for P. vivax and P. falciparum malaria
Study NCT00121134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Group A: Once every 3 weeks for 12 months Group B: Once every 3 weeks for 12 months
Study NCT00121134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Once a day for 6 months
Study NCT00121134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Twice daily for the first two days of every week for 6 months
Study NCT00121134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: 2000 mg/m2 a day, on Days 1-14 of a 21 day cycle, for at total of 6 cycles (18 weeks)~Bevacizumab: 15 mg/kg IV day 1 every 3 weeks x 1 year (17 cycles)
Study NCT00715936 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study NCT00715936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECD
Study NCT00715936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Nutrition
Study NCT01470768 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Amino Acid-based Formula with high DHA and ARA
Study NCT01470768 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Amino Acid-based Formula with lower DHA and ARA
Study NCT05748249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vertistop® D
Description: Vitamin D supplementation
Study NCT05748249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vertistop® D
Description: Vitamin D supplementation
Study NCT00742066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: Single dose 600mg orally
Study NCT00742066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Felodipine
Description: single dose 10mg Felodipine ER
Study NCT03554889 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK Cell adaptive transfer
Description: Nimotuzumab will enhance the ADCC effect of NK Cell adaptive transfer
Study NCT00742066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose tablet orally
Study NCT04325035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istaroxime
Description: Reconstituted istaroxime and lactose lyophilized powder delivered via IV infusion
Study NCT04325035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Reconstituted placebo (lactose lyophilized powder) delivered via IV infusion
Study NCT04325035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Reconstituted placebo (lactose lyophilized powder) delivered via IV infusion
Study NCT02656511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Dolutegravir 50 mg PO daily
Study NCT02656511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir
Description: Emtricitabine 200 mg/Tenofovir alafenamide 25 mg PO daily
Study NCT01399879 — intervention group
Intervention type: OTHER
Intervention: Faraday cage, movement stabilization
Description: The Faraday cage is a copper-mesh cage that surrounds the device and test site. It helps eliminate surrounding electrical noise. Movement stabilization will be achieved by placing a velcro strap over the arm to minimize random movements.
Study NCT05532371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training combined with lower limb strengthening
Description: The participants performed aerobic exercise training and lower limb strengthening during this intervention.
Study NCT05532371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-task training combined with lower limb strengthening group (DG)
Description: The participants performed dual-task training combined with lower limb strengthening during this intervention.
Study NCT05532371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training combined with dual-task training and lower limb strengthening
Description: The participants performed aerobic exercise training combined with dual-task training and lower limb strengthening during this intervention.
Study NCT03554889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab will enhance the ADCC effect of NK Cell adaptive transfer
Study NCT00792636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sumatriptan and naproxen sodium combination tablet
Description: sumatriptan 85mg and naproxen sodium 500mg
Study NCT00792636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sumatriptan tablet
Description: sumatriptan 85mg
Study NCT00792636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen sodium tablet
Description: Naproxen sodium 500mg
Study NCT01046136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: guaifenesin (Mucinex)
Description: bid 7 days
Study NCT01046136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: bid 7 days
Study NCT04373434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Homes/Healthy Families (HH/HF) Intervention
Description: The HH/HF Intervention involves coaching calls, text messages and intervention materials that are designed to increase behavioral capability, self-efficacy and behavioral intention to improve the home food environment for healthy eating and weight gain prevention. The intervention is delivered over a 12 week period.
Study NCT04373434 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants in the control condition will receive two mailings on healthy eating, the first from the Dietary Guidelines For Americans 2015-2020, 8th Edition and the second from Choose MyPlate. Additionally, both mailings will include a food diary from the Centers for Disease Control and Prevention. Mailings will be sent to participants one and six-weeks post-baseline. These materials focus on the same dietary outcomes being targeted in the HH/HF intervention, but without the home environment emphasis. Control group participants will receive their home environment profile with a list of healthy actions upon completion of the study.
Study NCT03592602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arm abduction and adduction
Description: All PICC lines will be placed under the guidance of intravascular ECG. Before the PICC placement procedure, basal ECG will be examed. During the procedure, intravascular ECG data will be collected with the punctured arm adduction and abduction while the catheter advances to the cavoatrial junction. After the procedure, chest X-ray radiographs will be taken with arms 90° abducted and adducted (i.e., 0°abducted) in a supine position.
Study NCT01462149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Description: Docetaxel 75mg/m2BAS, q 3 weeks, 3 cycles
Study NCT01462149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 5, q 3 weeks, 3 cycles
Study NCT05532371 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Only lower limb strengthening group (CG)
Description: The participants performed only lower limb strengthening group during this intervention.
Study NCT03751618 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hip arthroscopy
Description: Suture will be realized with two simple suture knots (non resorbable suture material). These suture knots will be performed at the end of hip arthroscopy. Correct capsular suture will be controlled under arthroscopy video.~Patients randomized in control arm will not received capsular suture at the end of the procedure.
Study NCT03751618 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hip arthroscopy
Description: Suture will be realized with two simple suture knots (non resorbable suture material). These suture knots will be performed at the end of hip arthroscopy. Correct capsular suture will be controlled under arthroscopy video.~Patients randomized in control arm will not received capsular suture at the end of the procedure.
Study NCT01234922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisinopril
Description: Given orally
Study NCT01234922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium
Description: Given orally
Study NCT01234922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01234922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: benazepril hydrochloride
Description: Given orally
Study NCT01234922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramipril
Description: Given orally
Study NCT00886223 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic robot-assisted sacropexy
Description: Repair of vaginal vault prolapse with laparoscopic sacropexy assisted by robotic surgical system (da Vinci®-System)
Study NCT01348412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 130 mg/m²Every 21 days
Study NCT01348412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltitrexed
Description: 3 mg/m² with a maximum of 6 mg every 21 days
Study NCT01348412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: other intravenous chemotherapy drugs
Study NCT03533738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food sequence 1
Description: Vegetables first then meat \& rice together
Study NCT03533738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food sequence 2
Description: Meat first then vegetables \& rice together
Study NCT03533738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food sequence 3
Description: Vegetables first then meat followed by rice
Study NCT01746641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Study NCT03533738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food sequence 4
Description: Vegetables first followed by meat and rice together
Study NCT01746641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study NCT02065193 — intervention group
Intervention type: BEHAVIORAL
Intervention: ADOS/ADI-R/Clinical assessment
Study NCT03533738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food sequence 5
Description: Rice first followed by vegetables \& meat together
Study NCT04171206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free From Abuse
Description: Participants in the treatment arm will watch a 15-minute talk given by an adult female survivor of IPV who tells the story of her abusive relationship. After watching the video, participants will read information on 10 signs of an unhealthy relationship. The intervention will take approximately 25 minutes to complete.
Study NCT04171206 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Technology and crime
Description: Participants in the placebo control arm will watch a 19-minute talk on technology development and crime. After watching the video, participants will read 10 facts about cyber security. The intervention will take approximately 25 minutes to complete.
Study NCT04699851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored recommendations
Description: Tailored informations delivered by email about health prevention behavior in a pandemic based on the answers in the survey.
Study NCT04699851 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General recommendation
Description: The control group will receive general recommendations by email about health prevention in a pandemic.
Study NCT05231330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silvernanoparticles
Description: silvernanoparticles in fluoride varnish
Study NCT05231330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SDF
Description: silver diamine fluoride
Study NCT05395455 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Treatment of patients with periodontitis was performed scaling and root planing by using manual and ultrasonic instruments.
Study NCT03067961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Salmonella Typhi (S. Typhi)
Description: Investigating the role of typhoid toxin in the pathogenesis of enteric fever
Study NCT03060629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Mos4.HIV
Description: Participants will receive Ad26.Mos4.HIV 5x10\^10 virus particles (vp) as 0.5 milliliter (mL) via Intramuscular (IM) into the left deltoid on Months 0, 3, 6, and 12.
Study NCT03060629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clade C gp140
Description: Participants will receive Clade C gp140 (250 mcg) mixed with Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.
Study NCT03060629 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo.
Study NCT06237998 — intervention group
Intervention type: DEVICE
Intervention: Telemedicine
Description: Patients receive equipment for report of vital signs and patient reported experience measures (PREMS), automatically transmitted via smartphone/bluetooth for six months (possible extension to 12 months in case of instability). A digital smartphone application is used for registration and transmission of data, including modes for asynchronous (chat) communication with the healthcare provider. Planned titration to OMT or diuretic adjustments may be done remotely depending on clinical assessment. The digital sensors include an electronic scale, pulse and blood pressure monitor for daily measurements by the patient.
Study NCT01666782 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Trivalent Influenza Vaccine
Description: Each 0.5 mL dose contains influenza split virus antigens formulated to contain a total of 45 mcg of influenza virus hemagglutinin, 15 mcg each from the 3 influenza virus strains in the vaccine.One dose given per patient.
Study NCT01666782 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-Dose Influenza Vaccine
Description: Each 0.5 mL dose of Fluzone High-Dose contains influenza split virus antigens that are formulated to contain a total of 180 mcg of influenza virus hemagglutinin, 60 mcg each from the 3 influenza virus strains in the vaccine. One dose given per patient.